Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Local Tolerability of Crisaborole 2% Ointment in Healthy Participants
NCT03760042Phase 1Completed
- Sponsor
- Pfizer
- Start
- Nov 2018
- Primary completion
- Apr 2019
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AN2728 ointment vehicle in atopic dermatitis (AD) (2 arms), sponsored by Pfizer. Primary endpoint: Treatment Emergent Adverse Events at Application Site at 3 days. Started Nov 2018; status: completed.
02
Drugs
AN2728 ointment vehicle
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03760042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03760042.